Bloodstream Infections Caused by Serratia marcescens: Have a High Prevalence of ESBL and Carbapenemase Production in Pediatric Patients

Tuğba Erat¹(ID), Halil Özdemir²(ID), Aysun Yahşi¹(ID), Tuğçe Tural Kara¹(ID), Ebru Azapağası²(ID), Tanıl Kendirli²(ID), Elif İnce¹(ID), Begüm Atasay¹(ID), Emel Ünal¹(ID), Derya Aysev³(ID), Erdal İnce¹(ID), Ergin Çiftçi¹(ID)

¹ Department of Pediatric Infectious Diseases, Ankara University Faculty of Medicine, Ankara, Türkiye
² Department of Pediatric Intensive Care Unit, Ankara University Faculty of Medicine, Ankara, Türkiye
³ Department of Pediatric Intensive Care Unit, Ankara University Faculty of Medicine, Ankara, Türkiye

Abstract

Objective: In this study, it was aimed to present a cohort study conducted retrospectively in order to examine the unexpected Serratia marcescens bacteremia prevalence in a children’s hospital in Türkiye.

Material and Methods: S. marcescens was isolated in the blood cultures of 45 patients at a 20-month period. Demographic features and clinical findings of the 45 patients including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, length of hospital stay and length of pediatric intensive care unit stay, portal of entry, duration of central venous catheter, results of antimicrobial susceptibility testing and 28-day all-cause mortality were examined. Bloodstream infections (BSI) were classified as BSI or catheter-related BSI. Definitions used to characterize antimicrobial resistant bacteria were classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR).

Results: Twelve patients (26.9%) had a malignancy. Mean hospitalization duration was 42.7 ± 41.4 (3-171) days. Central venous catheters (CVCs), including chemo-ports and Hickman catheters, were present in 43 patients during episodes of BSI. Twenty-four patients had primary BSI while 21 patients had catheter-related BSI. Mean length of CVC presence be-

Giriş: Bu çalışmanın amacı, 20 aylık bir dönem içerisinde kan kültüründe Serratia marcescens üreyen hastalarda beklenmedik bir artış olması ile bu hastaların demografik, klinik ve laboratuvar sonuçlarının incelemesi, mortaliteye yol açan özelliklerin ve dirençli suşlara tedavi yaklaşımının gözden geçirilmesidir.

Gereç ve Yöntemler: Kan kültüründe S. marcescens üreyen ve bakte-riyemi ile uyumu klinik bulguları olan hastalar genclik dönüms ürken hizmet verirken, Serratia marcescens üreyen hastaların mikrobiyolojik özellikleri, mortaliteye yol açan özelliklerin ve dirençli suşlara tedavi yaklaşımının gözden geçirilmesidir.

Bulgular: Hastaların 12 (%26.9)’sının altında vatan hastalığı maligniteydi. Oltalama hastanede kalış süresi 42.7 ± 41.4 (3-171) gündü. Kan yayım enfeksiyonları 43 hastada meydana geldi. 24 hastada prima SBI, 21 hastada kateterle ilişkili SBI meydana geldi. CVC perdeleri Kan yayım enfeksiyonlarının 28 günlük mortalitesi ve antibiyogram kaydedildi. Enfeksiyonlar kan yayım veya kateter ilişkili kan yayım enfeksiyonu olarak ayrıldı. Antimikrobiyel direnci değerlendirilmek için suşlar non-MDR, MDR, XDR ve PDR olarak sınıflandırıldı.

Bulgarlar: Hastaların 12 (%26.9)’sının altında vatan hastalığı maligniteydi. Oltalama hastanede kalış süresi 42.7 ± 41.4 (3-171) gündü. Kan yayım enfeksiyonları 43 hastada meydana geldi. 24 hastada prima SBI, 21 hastada kateterle ilişkili kan yayım enfeksiyonu meydana geldi. CVC perdeleri Kan yayım enfeksiyonlarının 28 günlük mortalitesi ve antibiyogram kaydedildi. Enfeksiyonlar kan yayım veya kateter ilişkili kan yayım enfeksiyonu olarak ayrıldı. Antimikrobiyel direnci değerlendirilmek için suşlar non-MDR, MDR, XDR ve PDR olarak sınıflandırıldı.
Introduction

Serratia species are opportunistic gram-negative bacteria classified in the Enterobacteriaceae family. S. marcescens is associated with severe and mortal nosocomial infections such as pneumonia, urinary and biliary tract infections, peritonitis, and intravenous catheter-related infections. S. marcescens can also be a significant nosocomial pathogen that might cause outbreaks (1-3). Epidemiologic data report that extended spectrum betalactamase (ESBL) and carbapenemase production is increasing in S. marcescens strains (4-6). Our study isolated S. marcescens strains with a high prevalence of ESBL and carbapenemase production within 20 months. S. marcescens bacteremia has a mortality rate varying between 25-58% (6-8). Our mortality rate was lower compared to that of other studies. Demographic and clinical characteristics of the patients, underlying diseases and treatment of the patients were recorded. The primary goal was to identify factors that were in correlation with S. marcescens-related mortality during the clustering period.

Materials and Methods

S. marcescens bacteremia features in a 270-bed children’s hospital in Ankara, Türkiye were examined as a retrospective cohort study. S. marcescens was isolated in the blood cultures of 45 patients within 20 months. Inclusion criteria for this study were positive blood cultures for S. marcescens and the presence of clinical bacteremia findings. Patient demographics and clinical features including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, hospitalization duration, length of pediatric intensive care unit stay (PICU) stay, the portal of entry, duration of the central venous catheter, antimicrobial susceptibility, and all-cause 28-day mortality were obtained from hospital medical data system.

Bloodstream infections (BSI) are classified as BSI or catheter-related BSI. Catheter-related BSI was considered in patients who had an intravascular device, ≥1 positive peripheral vein blood culture, clinical manifestations of infection in the absence of another apparent source for BSI. In order to identify a catheter-related BSI, a blood sample was taken from both the catheter and peripheral vein simultaneously, and culture growth was expected in the catheter culture at least two hours before peripheral blood culture (9).

Nosocomial BSI was defined as a positive blood culture obtained from patients who had been hospitalized for 48 hours or longer (10,11). Polymicrobial BSI was defined if more than one microorganism was identified in the same blood culture bottle.

Underlying diseases were defined under the international classification of diseases. The most common causes of hospitalization were hematono- oncological malignancy, cardiovascular diseases, prematurity, neuromuscular disease, and chronic lung diseases (12).

Identification of S. marcescens species was performed using conventional methods (BACTEC 9240, Becton Dickinson Diagnostic Instrument Systems, Sparks, Md.). Species identification and antimicrobial susceptibility testing were performed in local laboratories in accordance with European Committee on Antimicrobial Susceptibility Testing (EUCAST https://eucast.org) or Clinical and Laboratory Standards Institute (CLSI https://clsi.org) guidelines (13-15).

In recent years, multidrug-resistant Enterobacteriaceae isolates have been increasingly reported, and this resistance pattern and limited treatment options pose a great risk. Due to the increasing resistance pattern, the classification of resistant strains has been brought up. A group of international experts, including the European Centre for Disease Prevention and

Conclusion: It is a great concern that S. marcescens isolates are intrinsically resistant to polymyxins and produce ESBL and carbapenemase. Our mortality rate was reduced by high-dose prolonged infusion of meropenem and early catheter removal.

Keywords: ESBL, high-dose prolonged-infusion of meropenem, S. marcescens, pan-drug resistant

Introduction

Serratia species are opportunistic gram-negative bacteria classified in the Enterobacteriaceae family. S. marcescens is associated with severe and mortal nosocomial infections such as pneumonia, urinary and biliary tract infections, peritonitis, and intravenous catheter-related infections. S. marcescens can also be a significant nosocomial pathogen that might cause outbreaks (1-3). Epidemiologic data report that extended spectrum betalactamase (ESBL) and carbapenemase production is increasing in S. marcescens strains (4-6). Our study isolated S. marcescens strains with a high prevalence of ESBL and carbapenemase production within 20 months. S. marcescens bacteremia has a mortality rate varying between 25-58% (6-8). Our mortality rate was lower compared to that of other studies. Demographic and clinical characteristics of the patients, underlying diseases and treatment of the patients were recorded. The primary goal was to identify factors that were in correlation with S. marcescens-related mortality during the clustering period.

Materials and Methods

S. marcescens bacteremia features in a 270-bed children’s hospital in Ankara, Türkiye were examined as a retrospective cohort study. S. marcescens was isolated in the blood cultures of 45 patients within 20 months. Inclusion criteria for this study were positive blood cultures for S. marcescens and the presence of clinical bacteremia findings. Patient demographics and clinical features including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, hospitalization duration, length of pediatric intensive care unit stay (PICU) stay, the portal of entry, duration of the central venous catheter, antimicrobial susceptibility, and all-cause 28-day mortality were obtained from hospital medical data system.

Conclusion: It is a great concern that S. marcescens isolates are intrinsically resistant to polymyxins and produce ESBL and carbapenemase. Our mortality rate was reduced by high-dose prolonged infusion of meropenem and early catheter removal.

Keywords: ESBL, high-dose prolonged-infusion of meropenem, S. marcescens, pan-drug resistant

Introduction

Serratia species are opportunistic gram-negative bacteria classified in the Enterobacteriaceae family. S. marcescens is associated with severe and mortal nosocomial infections such as pneumonia, urinary and biliary tract infections, peritonitis, and intravenous catheter-related infections. S. marcescens can also be a significant nosocomial pathogen that might cause outbreaks (1-3). Epidemiologic data report that extended spectrum betalactamase (ESBL) and carbapenemase production is increasing in S. marcescens strains (4-6). Our study isolated S. marcescens strains with a high prevalence of ESBL and carbapenemase production within 20 months. S. marcescens bacteremia has a mortality rate varying between 25-58% (6-8). Our mortality rate was lower compared to that of other studies. Demographic and clinical characteristics of the patients, underlying diseases and treatment of the patients were recorded. The primary goal was to identify factors that were in correlation with S. marcescens-related mortality during the clustering period.

Materials and Methods

S. marcescens bacteremia features in a 270-bed children’s hospital in Ankara, Türkiye were examined as a retrospective cohort study. S. marcescens was isolated in the blood cultures of 45 patients within 20 months. Inclusion criteria for this study were positive blood cultures for S. marcescens and the presence of clinical bacteremia findings. Patient demographics and clinical features including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, hospitalization duration, length of pediatric intensive care unit stay (PICU) stay, the portal of entry, duration of the central venous catheter, antimicrobial susceptibility, and all-cause 28-day mortality were obtained from hospital medical data system.

Conclusion: It is a great concern that S. marcescens isolates are intrinsically resistant to polymyxins and produce ESBL and carbapenemase. Our mortality rate was reduced by high-dose prolonged infusion of meropenem and early catheter removal.

Keywords: ESBL, high-dose prolonged-infusion of meropenem, S. marcescens, pan-drug resistant

Introduction

Serratia species are opportunistic gram-negative bacteria classified in the Enterobacteriaceae family. S. marcescens is associated with severe and mortal nosocomial infections such as pneumonia, urinary and biliary tract infections, peritonitis, and intravenous catheter-related infections. S. marcescens can also be a significant nosocomial pathogen that might cause outbreaks (1-3). Epidemiologic data report that extended spectrum betalactamase (ESBL) and carbapenemase production is increasing in S. marcescens strains (4-6). Our study isolated S. marcescens strains with a high prevalence of ESBL and carbapenemase production within 20 months. S. marcescens bacteremia has a mortality rate varying between 25-58% (6-8). Our mortality rate was lower compared to that of other studies. Demographic and clinical characteristics of the patients, underlying diseases and treatment of the patients were recorded. The primary goal was to identify factors that were in correlation with S. marcescens-related mortality during the clustering period.

Materials and Methods

S. marcescens bacteremia features in a 270-bed children’s hospital in Ankara, Türkiye were examined as a retrospective cohort study. S. marcescens was isolated in the blood cultures of 45 patients within 20 months. Inclusion criteria for this study were positive blood cultures for S. marcescens and the presence of clinical bacteremia findings. Patient demographics and clinical features including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, hospitalization duration, length of pediatric intensive care unit stay (PICU) stay, the portal of entry, duration of the central venous catheter, antimicrobial susceptibility, and all-cause 28-day mortality were obtained from hospital medical data system.

Conclusion: It is a great concern that S. marcescens isolates are intrinsically resistant to polymyxins and produce ESBL and carbapenemase. Our mortality rate was reduced by high-dose prolonged infusion of meropenem and early catheter removal.

Keywords: ESBL, high-dose prolonged-infusion of meropenem, S. marcescens, pan-drug resistant

Introduction

Serratia species are opportunistic gram-negative bacteria classified in the Enterobacteriaceae family. S. marcescens is associated with severe and mortal nosocomial infections such as pneumonia, urinary and biliary tract infections, peritonitis, and intravenous catheter-related infections. S. marcescens can also be a significant nosocomial pathogen that might cause outbreaks (1-3). Epidemiologic data report that extended spectrum betalactamase (ESBL) and carbapenemase production is increasing in S. marcescens strains (4-6). Our study isolated S. marcescens strains with a high prevalence of ESBL and carbapenemase production within 20 months. S. marcescens bacteremia has a mortality rate varying between 25-58% (6-8). Our mortality rate was lower compared to that of other studies. Demographic and clinical characteristics of the patients, underlying diseases and treatment of the patients were recorded. The primary goal was to identify factors that were in correlation with S. marcescens-related mortality during the clustering period.

Materials and Methods

S. marcescens bacteremia features in a 270-bed children’s hospital in Ankara, Türkiye were examined as a retrospective cohort study. S. marcescens was isolated in the blood cultures of 45 patients within 20 months. Inclusion criteria for this study were positive blood cultures for S. marcescens and the presence of clinical bacteremia findings. Patient demographics and clinical features including age, sex, underlying diseases, white blood cell (WBC), C-reactive protein (CRP), serum albumin level, hospitalization duration, length of pediatric intensive care unit stay (PICU) stay, the portal of entry, duration of the central venous catheter, antimicrobial susceptibility, and all-cause 28-day mortality were obtained from hospital medical data system.
Control and the Centers for Disease Control and Prevention, has created a standardized international terminology to describe acquired resistance profiles in bacteria. For the defined Enterobacteriaceae, aminoglycosides, anti-MRSA cephalosporins, antipseudomonal penicillins-beta-lactamase inhibitors, carbapenems, third and fourth generation cephalosporins, cephemycins, fluoroquinolones, trimethoprim-sulphamethoxazole, tigecycline, monobactams, chloramphenicol, and fosfomycin have been used, and multidrug-resistance (MDR) has been defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories. Extensive drug-resistance (XDR) has been defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories, and pan-drug resistance (PDR) has been defined as non-susceptibility to all agents in all (16).

Since 45 positive S. marcescens blood cultures were reported within twenty months, a possible origin of cause for this clustering bacteremia was investigated. Hand cultures of medical staff and environmental samples were collected to determine carriers of S. marcescens. Twenty-three environmental samples were collected; fifteen were collected from the hands of medical staff nursing the patients. Furthermore, medical solutions, disinfectants, and taps were sampled for culture. All medical staff received training on preventing nosocomial infections.

The protocol for this retrospective study was approved by the ethics committee of a university medical school (Date: 26.02.2018, ethics committee approval number: 04-220-18). Data of the research was not used beyond scientific purposes.

**Statistical Analysis**

Continuous variables were presented with median, mean, standard deviation, minimum, and maximum values. The variables with normal distribution were evaluated with the Kolmogorov-Smirnov Test. Intergroups were analyzed with the Mann-Whitney U test and the Student’s t-test. All data analyses were performed using SPSS Version SPSS 15.0 (SPSS Inc., Chicago, IL, USA). Significance level was p < 0.05.

**Results**

Within twenty months, 45 S. marcescens BSI episodes were identified in 39 patients. BSI episodes with S. marcescens recurred at different times in six patients. The number of male patients was 24 (66.7%), and patients’ median age was 13 months (min-max 1-198 months). Twenty-eight of the patients whose blood cultures were positive for S. marcescens were hospitalized in PICU, eight of them in the neonatal intensive care unit, six of them in the pediatric hematology-oncology ward, and three of them in the pediatric surgery department. Patient demographics, clinical characteristics, and most common underlying diseases are shown in the Table 1.

The most common underlying disease was malignancy, and hematological disorders (26.9%), followed by neuromuscular diseases (22.2%), prematurity (17.7%), cardiovascular diseases (13.3%). Of the patients, 64.4% needed mechanical ventilation, and 26.7% received total parenteral nutrition. Median hospitalization duration was 31 (3-171) days-80% of the patients presented with bacteremia during the intensive care unit stay. Forty-three patients had CVCs, including chemoports and Hickman catheters, during BSI episodes. Primary BSI was diagnosed in 24 (53.3%) episodes, catheter-related BSI was considered in 21 episodes. Median CVC duration before catheter-related BSI was 31 (1-200) days. During the bacteremia episode, 24 catheters (55.8%) were removed.

According to our study sample, mean WBC was 13.870 ± 10.11/mm³ (min-max; 0.5-36.7/mm³); mean serum C-reactive protein (CRP) level was 124.7 ± 107.8 mg/L (min-max; 1-395 mg/L); and mean serum albumin level was 2.76 ± 0.62 g/dL (min-max; 1-4.1 g/dL). Four patients (8.9%) died during the bacteremia episode. Mean WBC was 17.200 ± 14.79/mm³, mean serum CRP level was 147.2 ± 80.79 mg/L, and mean serum albumin level was 2.43 ± 0.23 g/dL in the fatal group.

In total, 45 blood cultures were positive for S. marcescens, and 17.8% (eight patients) of the BSI episode were polymicrobial. Five of the cultures revealed Klebsiella pneumonia; two of them revealed Pseudomonas aeruginosa and one Acinetobacter baumannii. In one patient in the neonatal intensive care unit, S. marcescens was found positive in the cerebrospinal fluid and blood culture simultaneously.

Twenty-six (57.8%) isolates of S. marcescens produced extended-spectrum beta-lactamases (ESBL), and eighteen (40%) isolates produced carbapenemase. Isolates of two of the patients who died produced ESBL and carbapenemases. Nineteen (42.2%) of them were non-MDR, fourteen (31.1%) were MDR, eleven (24.4%) were XDR, one (2.2%) was PDR (Figure 1). S. marcescens isolates were examined in the fatal group; two had MDR, one had non-MDR, and one had XDR.

All patients received antimicrobial treatment: five (11.1%) patients were treated with monotherapy, 16 (35.5%) received a combination of two antibiotics, and 24 (53.4%) were treated with a regimen including ≥3 antibiotics. All XDR and three MDR isolates were treated with a high-dose prolonged infusion of meropenem. The most common regimes received for XDR isolates were a high-dose prolonged meropenem infusion, amikacin, levofloxacin, and tigecycline. Most of the patients with MDR isolates received meropenem, amikacin, and levofloxacin.

The medical staff’s hands and environmental cultures were negative. The medical staff received training for nosocomial infections.
Discussion

*S. marcescens* is a severe nosocomial infection cause. Furthermore, multidrug-resistant *S. marcescens* strains are known to increase (4,7,17,18).

Within twenty months, 45 BSI episodes were identified in our study, and blood cultures were positive for *S. marcescens* with a high prevalence of ESBL and carbapenemase production. The all-cause 28-day mortality rate was 8.9%. Herein, it was aimed to examine patients’ demographics, clinical characteristics, the most common underlying diseases, and treatment. In addition, the factors associated with *S. marcescens*-related mortality were aimed to be identified.

Table 1. Patient demographics, clinical characteristics and most common underlying diseases of the patients with *S. marcescens* bacteremia

| Characteristics                                      | Total cases (n= 45) | Fatal group | Non-fatal group |
|------------------------------------------------------|--------------------|-------------|-----------------|
| Age, month, median                                   | 37.6 (1-198)       | 80.75       | 33.35           |
| Male, n (%)                                          | 24 (66.7)          | 3           | 21              |
| Underlying disease, n (%)                            |                    |             |                 |
| Hematological-oncological disorders                  | 12 (26.9)          | 1           | 11              |
| Neuromuscular disease                                | 10 (22.2)          |             | 10              |
| Prematurity                                          | 8 (17.7)           |             | 8               |
| Cardiovascular diseases                              | 6 (13.3)           | 2           | 4               |
| Abdominal surgery                                    | 5 (11.1)           |             | 5               |
| Liver transplantation                                | 1 (2.2)            |             | 1               |
| Immune deficiency                                    | 1 (2.2)            |             | 1               |
| Chronic lung disease                                 | 1 (2.2)            |             | 1               |
| Metabolic syndrome                                   | 1 (2.2)            |             | 1               |
| Service, n (%)                                       |                    |             |                 |
| PICU                                                 | 28 (62.2)          |             |                 |
| NICU                                                 | 8 (17.7)           |             |                 |
| Hematology-oncology                                  | 6 (13.3)           |             |                 |
| Pediatric surgery                                    | 3 (6.6)            |             |                 |
| Had CVC, n                                           | 43                 |             |                 |
| Clinical manifestation, n (%)                        |                    |             |                 |
| BSI                                                  | 24 (53.3)          | 3           | 21              |
| CR-BSI                                               | 21 (46.7)          | 1           | 20              |
| Bacteria resistance profile, n (%)                   |                    |             |                 |
| Non-MDR                                              | 19 (42.2)          | 1           | 18              |
| MDR                                                  | 14 (31.1)          | 2           | 12              |
| XDR                                                  | 11 (24.4)          | 1           | 10              |
| PDR                                                  | 1 (2.2)            | 1           | 1               |
| Polymicrobial, n (%)                                  | 8 (17.8s)          | 0           | 8               |
| Laboratory data                                       |                    |             |                 |
| Leukocyte count/mm³                                   | 13.87 (0.5-36.7)   | 17.20       | 13.54           |
| C-reactive protein level mg/L                        | 124.7 (1-395)      | 147.2       | 122.5           |
| Serum albumin level (g/dL)                           | 2.76 (1.4-1.1)     | 2.43        | 2.79            |
| Catheter removal                                      | 24 (55.8)          | 3           | 21              |
| Length of hospital stay, day (mean)                  | 43.20 (3-171)      | 42.7        | 38.5            |
| The duration of CVC prior to catheter related BSI, day (mean) | 47.9 (1-200)       | 46.02       | 32.50           |
| 28-day outcome, n (%)                                | 4 (8.9)            |             |                 |

PICU: Pediatric intensive care unit, NICU: Neonatal intensive care unit, CVC: Central venous catheter, BSI: Bloodstream infections, CR-BSI: Catheter-related bloodstream infections, MDR: Multidrug-resistant, XDR: Extensively drug-resistant, PDR: Pandrug-resistant.
Cheng et al. (19) have demonstrated a prevalence of 12% for ESBL production among S. marcescens. Bouchillon et al. (20) have reported that the percentage of carbapenem-resistant S. marcescens remained low worldwide, as less than or equal to 2%. However, in our study, 57.8% of the isolates of S. marcescens produced ESBL, and 40% of the isolates produced carbapenemase. Choi et al. (18) have reported that the most critical risk factor for resistant Serratia bacteremia was using a second or third-generation cephalosporin priorly. Our study patients were hospitalized in the intensive care unit, had underlying diseases, and used a broad spectrum of antimicrobial therapy; therefore, a high antibiotic resistance pattern was seen. S. marcescens isolates are naturally resistant to polymyxins, and those producing ESBL and carbapenemase severely constitute a concern. Therefore, therapeutic options available for treatment were limited.

Increased morbidity and mortality with multiple drug-resistant strains has led to the search for new treatment modalities. Previous studies have reported double carbapenem combination, prolonged antimicrobial categories, high-dose prolonged-infusion of carbapenem, or combined salvage therapies with colistin, amikacin, levofloxacin, and tigecycline for patients with multidrug-resistant Enterobacteriaceae isolates (21-25). The dose of meropenem in systemic infections other than meningitis is 20 mg/kg/dose, by infusion every eight hours for 30 minutes. Beta lactam antibiotics demonstrate a time-dependent effect on bacterial eradication. Therefore, after the concentration at which maximum killing is achieved, it is more effective to prolong the time remaining above this concentration rather than increasing the dose of beta lactam antibiotics. A prolonged infusion strategy has a greater likelihood of attaining pharmacokinetic/pharmacodynamic targets and may offer clinical benefit in patients with severe infections or less susceptible pathogens (26). In our study, 24 (53.4%) patients were treated with a regimen including ≥3 antibiotics. All XDR (11 patients) and three MDR isolates were treated with high-dose prolonged-infusion of meropenem (meropenem was dosed at 30 mg/kg/dose intravenously every six hours, infused three hours). The most common regimes received for XDR isolates were prolonged high-dose meropenem infusion, amikacin, levofloxacin, and tigecycline in our patients. Most of the patients with MDR isolates received meropenem, amikacin, and levofloxacin.

Laboratory finding of the patients who died were also examined. Mean WBC and mean serum CRP levels were higher compared to the non-fatal group. Mean serum albumin level was lower than the fatal-group. Kim et al. (7) have reported similar results in their research and revealed that these findings are related to mortality. In addition, underlying diseases are seen as the other factor of mortality in most of our patients. Four patients died in this 28-day period, and one of them had standard risk B-cell ALL with neutropenic phase while one patient had SCID. The other two patients had congenital heart diseases and heart failure, and they were supported with extracorporeal membrane oxygenation. In contrast, one other patient who had high-risk B-cell ALL and catheter-related BSI with pan drug resistance isolates survived. The important factor in this patient was that he was not in the neutropenic phase, and his catheter was removed in the early stage of infection under triple antibiotic combined therapy (high-dose prolonged-infusion of meropenem, amikacin, levofloxacin).

Among the limitations of the study; clustering of S. marcescens reproductions within 20 months makes us think of a healthcare-associated outbreak, but we could not show the factor in the environmental samples or in the hands of the medical staff.

**Conclusion**

In our study, reasons for lower mortality rate could be related to high-dose prolonged carbapenem infusion, combined dual or triple antibiotic treatment, and early removal of CVCs. We want to emphasize the role of S. marcescens in bacteremia and highlight the importance of surveillance procedures and hospital staff education. All cultures obtained from the medical staff's hands and environment were negative. However, bacteremia with the same resistant strains was not observed after surveillance procedures.

**Acknowledgments**

We thank all the patients and their families involved in the study and all health care workers involved in the diagnosis and treatment of patients.
Ethics Committee Approval: Ethical approval was obtained from the Ankara University Faculty of Medicine Ethics Committee (Decision no: 04-220-18, Date: 26.02.2018).

Informed Consent: Patient consent was obtained.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept- TE, HÖ, AY, EA, TK; Design- TE, HÖ, AY, EA, TK, EI; Supervision- TTK, EI, BA, EÖ, DA, EI; Resource- TTK, BA, EÖ, DA, EÜ; Data Collection and/or Processing- TE, EÜ, EI, BA, EI; Analysis and/or Interpretation- TE, EÇ, EI, HÖ; Literature Search – TE, AY, TTK, TK, EI; Writing- TE, EÇ, EI, HÖ; Critical Review- .

Conflict of Interest: All authors declare that they have no conflicts of interest or funding to disclose.

Financial Disclosure: The authors declared that this study has received no financial support.

References

1. Ballot DE, Bandini R, Nana T, Bosman N, Thomas T, Davies VA, et al. A review of multidrug-resistant Enterobacteriaceae in a neonatal unit in Johannesburg, South Africa. BMC Pediatr 2019;19(1):320. [CrossRef]
2. Roshenthal VD, Belkebir S, Zand F, Afeef M, Tanzi VL, Al-Abdely HM, et al. Six-year multicenter study on short-term peripheral venous catheters-related bloodstream infection rates in 246 intensive units of 83 hospitals in 52 cities of 14 countries of Middle East: Bahrain, Egypt, Iran, Jordan, Kingdom of Saudi Arabia, Kuwait, Lebanon, Morocco, Pakistan, Palestine, Sudan, Tunisia, Turkey, and United Arab Emirates-International Nosocomial Infection Control Consortium (INICC) findings. J Infect Public Health 2020;13(8):1134-41. [CrossRef]
3. Bard JD, Hindler JF, Lewinski MA. Carbapenemase-Producing Serratia marcescens: The treatment Conundrum. Clin Microbiol Newsl 2010;32:77-8. [CrossRef]
4. Batah R, Loucif L, Olaitan AO, Boutefnouchet N, Allag H, Rolain JM. Outbreak of Serratia marcescens coproducing ArmA and CTX-M-15 mediated high levels of resistance to aminoglycoside and extended-spectrum beta-lactamases, Algeria. Microb Drug Resist 2015;21:470-6. [CrossRef]
5. Xu Q, Fu Y, Zhao F, Jiang Y, Yu Y. Molecular characterization of carbapenem-resistant Serratia marcescens clinical isolates in a tertiary hospital in Hangzhou, China. Infection and Drug Resistance 2020:13:999-1008. [CrossRef]
6. Yu WL, Lin CW, Wang DY. Serratia marcescens bacteremia: Clinical features and antimicrobial susceptibilities of the isolates. J Microbiol Immunol Infect 1998;31:171-9. [CrossRef]
7. Kim SB, Jeon YD, Kim JH, Ann HW, Choi H, et al. Risk factors for mortality in patients with Serratia marcescens bacteremia Yonsei Med J 2015;56:348-54. [CrossRef]
8. Shih HJ, Lee HC, Lee NY, Chang CM, Wu CJ, Wang RL, et al. Serratia marcescens bacteremia at a medical center in southern Taiwan: High prevalence of cefotaxime resistance. J Microbiol Immunol Infect 2005;38:350-7. [CrossRef]
9. Mermel LA, Allon M, Bouza E, Flynn P, O’Grady NP, Raad II, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45. [CrossRef]
10. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections 1988. Am J Infect Control 1988;16:128-40. [CrossRef]